EUVIMEDEUVIMED entdecken
Leitlinie

Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy

Iwona Rościszewska-Żukowska iD, Alina Kułakowska iD, Alicja Kalinowska iD, Halina Bartosik-Psujek iD, Dagmara Mirowska-Guzel iD, Mariusz Stasiołek iD, Beata Zakrzewska-Pniewska, Waldemar Brola iD, Sławomir Wawrzyniak, Marek Gołębiowski, Jacek Mackiewicz, Grażyna Kamińska-Winciorek und 6 weitere

Neurologia i Neurochirurgia Polska · 2025

DOI: 10.5603/pjnns.101995 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Neurologia i Neurochirurgia Polska, 2025. Verfasst von Iwona Rościszewska-Żukowska und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland. iwona.rosciszewska@op.pl. Hauptthemen laut MEDLINE: Immunologic Factors, Immunomodulating Agents, Immunosuppressive Agents, Multiple Sclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that is usually diagnosed between the ages of 20 and 40. Changes in the immune system also observed in cancer may suggest a higher prevalence of cancer in the MS patient population. In recent years, many highly effective immunosuppressive drugs have been introduced into disease-modifying therapy (DMT) which may be associated with a higher risk of cancer development in patients with MS. This paper presents current data on the oncological risk of individual drugs. In addition, it provides recommendations on the management for qualifying for DMT and monitoring the safety of the therapy from anoncological perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunologic FactorsImmunomodulating AgentsImmunosuppressive AgentsMultiple SclerosisNeoplasmsHumansPolandSocieties, Medical

Stichwörter der Autor:innen

cancerimmunomodulatory therapymultiple sclerosisoncological risk

Substanzen

Immunologic FactorsImmunomodulating AgentsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland. iwona.rosciszewska@op.pl.
  • Department of Neurology, Medical University of Bialystok, Bialystok, Poland.
  • Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poznan, Poland.
  • Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Poland.
  • Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland.
  • Department of Neurology, Medical University of Lodz, Lodz, Poland.

ORCID-Profile: Iwona Rościszewska-Żukowska, Alina Kułakowska, Alicja Kalinowska, Halina Bartosik-Psujek, Dagmara Mirowska-Guzel, Mariusz Stasiołek, Waldemar Brola

Zitieren

APA

Rościszewska-Żukowska, I., Kułakowska, A., Kalinowska, A., Bartosik-Psujek, H., Mirowska-Guzel, D., Stasiołek, M., Zakrzewska-Pniewska, B., Brola, W., Wawrzyniak, S., Gołębiowski, M., Mackiewicz, J., Kamińska-Winciorek, G., Czarnecka, A. M., Maciejczyk, A., Giebel, S., Rutkowski, P., Cybulska-Stopa, B., & Adamczyk-Sowa, M. (2025). Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy. Neurologia i Neurochirurgia Polska. https://doi.org/10.5603/pjnns.101995

Vancouver

Rościszewska-Żukowska I, Kułakowska A, Kalinowska A, Bartosik-Psujek H, Mirowska-Guzel D, Stasiołek M, et al. Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy. Neurologia i Neurochirurgia Polska. 2025. doi:10.5603/pjnns.101995

BibTeX
@article{Rociszewskaukowska2025,
  author = {Rościszewska-Żukowska, Iwona and Kułakowska, Alina and Kalinowska, Alicja and Bartosik-Psujek, Halina and Mirowska-Guzel, Dagmara and Stasiołek, Mariusz and Zakrzewska-Pniewska, Beata and Brola, Waldemar and Wawrzyniak, Sławomir and Gołębiowski, Marek and Mackiewicz, Jacek and Kamińska-Winciorek, Grażyna and Czarnecka, Anna M and Maciejczyk, Adam and Giebel, Sebastian and Rutkowski, Piotr and Cybulska-Stopa, Bożena and Adamczyk-Sowa, Monika},
  title = {Recommendations of Multiple Sclerosis and Neuroimmunology Section of Polish Neurological Society and Immuno-oncology Section of Polish Society of Oncology on oncological risk in patients with multiple sclerosis undergoing immunomodulatory therapy},
  journal = {Neurologia i Neurochirurgia Polska},
  year = {2025},
  doi = {10.5603/pjnns.101995}
}
Kostenlos starten →